Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (November 2025)
27 slides from Sanara Medtech's investor presentation, Nov 26, 2025
Slide 1: Sanara MedTech Investor Presentation
Sanara MedTech Investor Presentation November 2025
Slide 2: Forward-looking statements
Sanara MedTech * This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements
Slide 3: Sanara MedTech: Key Attributes
Sanara MedTech: Key Attributes «> Sanara 9 MedTech Business Snapshot vos Invest it Highlights Sanara MedTech at a Glance Ticker (Nasdaq) + Significant commercial scale, with a multi-year track record of high growth Market Cap $193M) + Compelling margin profile and demonstrated profitability Avg. Dai
Slide 4: Sanara MedTech: Who We Are
Sanara MedTech: Who We Are Mission Statement & Product Portfolio Strategy Sanara Our mission: Develop and commercialize transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. Our offering: Differentiated tissue repair products that facilit
Slide 5: Sanara's Unique Position
Sanara’s Unique Position Three Pillars of our Surgical Market Advantage * Established formula positions Sanara for strong, sustainable growth and profitability Differentiated Proven Surgical Technologies Go-to-Market Strategy + Commercial distribution network has delivered strong growth, significant
Slide 6: Sanara Historical Net Revenue
Sanara Historical Net Revenue «) Sanara Demonstrated Track Record of Strong, Sustained Growth id MedTech Net Revenue in millions $ $100.0 TTM Net Revenue: $101.9M $90.0 $86.7 Biologics, LCC ‘Acquisition (uly 2022) $80.0 $70.0 $60.0 $50.0 $40.0 $30.0 $20.0 $10.0 oo = 2024
Slide 7: Quarterly Performance
Quarterly Performance Net Revenue & Ad Net Revenue in millions $ $30.0 $25.0 $20.0 $15.0 $10.0 $5.0 EBITDA® Growth mm Quarterly Sales mmBIASURGE® Spike —Adj. EBITDA $263 $234 saz 20.2 7 s4a $185 3177 \ $155 $158 $16.0 \ sar 12023 22023 3.2023 at.2023 «= atz0z4 «2.2024 ©3202 ©2024 © at2025 «= aaze2s
Slide 8: Products and Distribution
Products and Distribution
Slide 9: Find Your Winning Advantage
Find Your WINNING ADVANTAGE with leading-edge surgical solutions a th/ (fee CONE eos FORTIFY tre” FORTIFY riowasie BiFORM BiASinGe TEXAGEN’ ALLOCYTE+ ACTIGEN’
Slide 10: Sales & Distribution Network
Sales & Distribution Network Sales & Distribution Overview “) TTM Heat Map ba ia All commercial products are made in the U.S. except BIASURGE®, which is exempt from tariffs as of 11/21/25. ‘TTM Net Revenue $101.9M (81% YoY Growth) Facilities 4,000+ Approvals (1,400+ Active) Distributors 400+ Agreeme
Slide 11: Clinical Evidence
Clinical Evidence Key Products Supported by Expanding Portfolio of Peer-Reviewed Studies” Pre-Clinical Advances in Wound Care Hydrolyzed Collagen Powder Dressing Improves Wound Inflammation, Perfusion, and Breaking Strength of Repaired Tissue. Multispecialty Journal of Surgery Activated Collagen Pow
Slide 12: Key Growth Drivers
Key Growth Drivers How We Grow and Scale Our Product Portfolio Penetrate Existing Hospital Customers Expand Hospital Customer Footprint + Add new surgeon users within the 1,400+ + Add new hospital customers from the € facilities we currently serve 4,000+ facilities where our products are contracted
Slide 13: New Product Pipeline
New Product Pipeline Upcoming Launch of OsStic™ + U.S. commercial launch of OsStic™ Synthetic Injectable Structural Bio-Adhesive Bone Void Filler * Targeted for Q1 2027 following anticipated FDA 510(k) clearance * Initial focus on treating +100,000 periarticular fractures occurring annually in the U
Slide 14: Sanara's Future Outlook
Sanara’s Future Outlook 2026 Highlights Sanara MedTech Pri s and Strategy for 2026 Maintain sales growth rate through expansion of internal salesforce and distributor partners Leverage new sales data analytics to gain better efficiencies within the sales channel Continue to strengthen patent protect
Slide 15: Financial Highlights
Financial Highlights
Slide 16: 3Q 2025 Financial Highlights
Sanara MedTech 3Q 2025 Financial Highlights Net Revenue ($M) Adjusted EBITDA ($M) $4.9 $26.3 s200 $217 $80 eee so $2.6 e200 0 s1s0 $10.0 20 $50 $10 + + 3Q24 3Q25 3Q24 3Q25 22% year-over-year net revenue growth Adjusted EBITDA increase of $2.3M from prior year period (") 3Q25 Highlights: + 22% net re
Slide 17: YTD 2025 Financial Highlights
YTD 2025 Financial Highlights «> Sanara MedTech Net Revenue ($M) Adjusted EBITDA ($M) $75.6 $12.3 $200 $60.4 sido 8700 si20 S00 si00 $500 $5.1 S400 so $300 360 $200 $40 s100 $20 8 $ yrp2024 yTD2025 yTp2024 yTD2025 25% year-over-year net revenue growth Adjusted EBITDA increase of $7.2M from prior yea
Slide 18: TTM 2025 Financial Highlights
TIM 2025 Financial Highlights Sanara MedTech Net Revenue ($M) Adjusted EBITDA ($M) $101.9 $164 si200 0.0 $78.1 “ s1000 $80.0 S50 $6.6 s600 s100 soo “ “7 200 ‘ ‘ TIM 2024 Tr 2028 71M 2024 7M 2025 31% year-over-year net revenue growth Adjusted EBITDA increase of $9.8M from prior year period (2) TTM 20
Slide 19: Appendix
Appendix
Slide 20: Financial Summary — Q3-2025 (1/2)
Financial Summary — Q3-2025 ©) Sanara Unaudited (1/2) : MedTech Net Revenue + Net revenue for the third quarter of 2025 was $26.3 million, compared to $21.7 million for the third quarter of 2024, an increase of $4.7 million, or 22%, year-over-year. + The increase in net revenue was driven by an incr
Slide 21: Financial Summary — Q3-2025 (2/2)
Financial Summary — Q3-2025 Unaudited (2/2) ©) Sanara MedTech Net Income (Loss) + Net income from continuing operations for the third quarter of 2025 was $0.8 million, compared to a net loss from continuing operations of $0.2 million for the third quarter of 2024. + Net loss from discontinued operat
Slide 22: Non-GAAP Financial Measures
«) Sanara MedTech Non-GAAP Financial Measures Use of Non-GAAP Financial Measures To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we present certain non-GAAP financial measures in this presentation,
Slide 23: Consolidated results of operations
Consolidated results of operations (reflecting our surgical business) for the periods indicated below (Unaudited) Sanara MedTech 2s 1 an) NetRevenve SERIE osaniase TERE RET 134967 1937282 1STADIN 564665 SHG 2008686 191HT 2209.18 KIVVIOL 26S DINTSIG 178130 _17ARI 7843721 299129 BA669T) ANGUS OISTOL 1
Slide 24: Reconciliation of Net income (loss) to Adjusted EBITDA
Reconciliation of Net income (loss) from continuing operations to = Sanara Adjusted EBITDA for the periods indicated below (Unaudited) f MedTech 25 24 2003 a i a ee a a a a a Net income (loss) fom continuing operations 577620366) 5300259 SH34AoS STG IBS TATTAS) SAAS SIS) SABOARH) SHR4,7OS STII SRD)
Slide 25: Reconciliation to Adjusted EBITDA: Three Months Ended September 30
Net income (loss) from continuing operations Adjustments: Interest expense Depreciation and amortization Noneash share-based compensation Change in fair value of earnout abilities Share of losses from equity method investments Gain on disposal of property and equipment Interest income Executive sepa
Slide 26: Reconciliation to Adjusted EBITDA: Trailing Twelve Months
Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA Net income (loss) from continuing operations. Adjustments: Interest expense Depreciation and amortization ‘Noneash share-based compensation Change in fair value of earnout liabilities Share of losses from equity method
Slide 27: Thank You
Thank You
Sanara MedTech — Investor Presentation (November 2025) on 6ix